MAIA Biotechnology (MAIA) Expected to Announce Earnings on Thursday

MAIA Biotechnology (NYSEAMERICAN:MAIA) will likely be announcing its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.

MAIA Biotechnology Trading Up 1.3 %

MAIA Biotechnology stock opened at $1.60 on Thursday. MAIA Biotechnology has a 1-year low of $1.29 and a 1-year high of $5.99. The stock has a market capitalization of $41.86 million, a price-to-earnings ratio of -1.16 and a beta of 0.20. The business’s 50-day moving average price is $1.94.

Insider Activity at MAIA Biotechnology

In other news, Director Stan Smith bought 25,000 shares of MAIA Biotechnology stock in a transaction on Friday, December 13th. The shares were purchased at an average price of $1.87 per share, for a total transaction of $46,750.00. Following the acquisition, the director now owns 1,130,060 shares of the company’s stock, valued at approximately $2,113,212.20. The trade was a 2.26 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 36.98% of the stock is owned by company insiders.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.